{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.65","value":"468.07"},{"groupId":"OG001","spread":"15.52","value":"382.36"},{"groupId":"OG002","spread":"15.65","value":"406.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants in Cohort 1 with baseline and at least 1 post-baseline assessment; uninfected HCC, HCV-infected, and HBV-infected participants reported together as pre-specified.","reportingStatus":"POSTED","timeFrame":"At Cycle 3 Day 1 (Each Cycle = 2 Weeks)","title":"Effective T-Half (T-HALF)","type":"SECONDARY","unitOfMeasure":"Hour"}